AMITRIPTYLINE TABLET

Country: Kanada

Bahasa: Inggeris

Sumber: Health Canada

Bahan aktif:

AMITRIPTYLINE HYDROCHLORIDE

Boleh didapati daripada:

SIVEM PHARMACEUTICALS ULC

Kod ATC:

N06AA09

INN (Nama Antarabangsa):

AMITRIPTYLINE

Dos:

50MG

Borang farmaseutikal:

TABLET

Komposisi:

AMITRIPTYLINE HYDROCHLORIDE 50MG

Laluan pentadbiran:

ORAL

Unit dalam pakej:

100/1000

Jenis preskripsi:

Prescription

Kawasan terapeutik:

TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS

Ringkasan produk:

Active ingredient group (AIG) number: 0101524003; AHFS:

Status kebenaran:

CANCELLED POST MARKET

Tarikh kebenaran:

2018-11-01

Ciri produk

_Pr_
_AMITRIPTYLINE _
_1 of 10 _
PRODUCT MONOGRAPH
Pr
AMITRIPTYLINE
(Amitriptyline Hydrochloride, USP)
10mg, 25mg, and 50mg tablets
Antidepressant
Sivem Parmaceuticals ULC
4705 Dobrin Street
Saint-Laurent, Quebec
Canada H4R 2P7
www.sivem.ca
Date of Preparation:
February 03, 2016
Control Number: 191591
_Pr_
_AMITRIPTYLINE _
_ 2 of 10 _
ACTION
Amitriptyline hydrochloride is a tricyclic antidepressant with
sedative properties. Its
mechanism of action in man is not known. Amitriptyline inhibits the
membrane pump
mechanism responsible for the re-uptake of transmitter amines, such as
norepinephrine and
serotonin, thereby increasing their concentration at the synaptic
clefts of the brain.
Amitriptyline has pronounced anticholinergic properties and produces
EKG changes and
quinidine-like effects on the heart (See ADVERSE REACTIONS). It also
lowers the
convulsive threshold and causes alterations in EEG and sleep patterns.
Orally administered amitriptyline is readily absorbed and rapidly
metabolized. Steady-state
plasma concentrations vary widely and this variation may be
genetically determined.
Amitriptyline is primarily excreted in the urine, mostly in the form
of metabolites, with some
excretion also occurring in the feces.
INDICATIONS
AMITRIPTYLINE (amitriptyline hydrochloride USP) is indicated for the
relief of symptoms of
depressive illness.
CONTRAINDICATIONS
Known hypersensitivity. Amitriptyline should not be given
concomitantly with or within at
least 14 days following the discontinuance of a MAO inhibitor. Then
initiate dosage of
amitriptyline cautiously with gradual increase in dosage until optimum
response is achieved.
Amitriptyline is not recommended during the acute recovery phase
following myocardial
infarction, and in the presence of acute congestive heart failure.
WARNINGS
Arrhythmias, sinus tachycardia, and prolongation of the conduction
time have been reported,
particularly with high doses of amitriptyline. A few instances of
unexpected death have been
reported in patients with cardiovascular disorders. M